Caris Life Sciences (CAI) Fundamental Analysis: Revenue, Earnings & Valuation

9.28 / 10

Outperform

Fundamentals rank Outperform with a 9.3/10 health rating. Cash‑to‑market (Cash‑MV) and operating cash flow YoY are strong, boosting the 9.28 fund score. However, net‑income‑to‑revenue and EPS growth lag, tempering the otherwise solid financial picture.

Analysis Checks(4/10)

Revenue-MV

Value-0.99

Score0/3

Weight-41.63%

1M Return-4.84%

Net cash flow from operating activities per share (YoY growth rate %)

Value-29.93

Score0/3

Weight-19.97%

1M Return-2.26%

Inventory turnover ratio

Value5.29

Score2/3

Weight21.31%

1M Return1.88%

Net income-Revenue

Value0.72

Score1/3

Weight7.19%

1M Return0.69%

Basic earnings per share (YoY growth rate %)

Value69.79

Score0/3

Weight-8.15%

1M Return-0.88%

Total profit (YoY growth rate %)

Value75.85

Score2/3

Weight38.07%

1M Return3.08%

Net cash flow from operating activities (YoY growth rate %)

Value133.91

Score3/3

Weight71.18%

1M Return5.49%

Cash-UP

Value-0.57

Score1/3

Weight8.61%

1M Return0.84%

Diluted earnings per share (YoY growth rate %)

Value69.79

Score0/3

Weight-8.51%

1M Return-0.92%

Cash-MV

Value-1.40

Score2/3

Weight31.90%

1M Return2.77%

Is CAI undervalued or overvalued?

CAI scores 9.28/10 on fundamentals and holds a Discounted valuation at present. Backed by its -358.49% ROE, -8.38% net margin, -10.12 P/E ratio, 9.43 P/B ratio, and 69.79% earnings growth, these metrics solidify its Outperform investment rating.